Biotricity (BTCY) Stock Price, News & Analysis

Company Overview

Biotricity (OTCMKTS:BTCY) is a medical device and digital health company specializing in remote cardiovascular monitoring and chronic disease management. The company’s flagship offering, the Bioflux system, integrates a wearable ECG patch with a cloud-based analytics platform to deliver real-time heart rhythm data and diagnostic insights. By combining wireless biosensors, mobile applications, and secure data transmission, Biotricity aims to simplify patient monitoring for healthcare providers and enhance early detection of arrhythmias and other cardiac events.

In addition to its core ambulatory ECG solution, Biotricity provides a suite of digital health products designed for broader chronic care management. These include a patient-facing mobile app for symptom tracking and medication reminders, as well as a clinician portal that aggregates and visualizes patient data. The company’s technology is engineered to meet regulatory requirements in multiple markets, including FDA clearance in the United States and CE Mark approval in Europe, positioning Biotricity to serve healthcare systems, telehealth providers, and home health agencies worldwide.

Founded in 2011 and headquartered in the San Francisco Bay Area, Biotricity leverages a multidisciplinary leadership team drawn from the medical device, software development, and clinical research sectors. Under the guidance of founder and CEO Kenneth Tam, the company has grown its operational footprint across North America and Europe, forging partnerships with cardiology practices and remote monitoring service providers. Biotricity continues to focus on innovative sensor technology and data analytics to drive improved patient outcomes and reduce the burden on healthcare facilities.

Key Stats

• Today's Range: $0.67 to $0.70
• 50-Day Range: $0.36 to $0.73
• 52-Week Range: $0.19 to $0.83
• Volume: 10,519 shs
• Average Volume: 37,331 shs
• Market Capitalization: $16.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BTCY Stock Analysis - Frequently Asked Questions

How have BTCY shares performed this year?

Biotricity's stock was trading at $0.2899 at the start of the year. Since then, BTCY stock has increased by 131.5% and is now trading at $0.6710.

How were Biotricity's earnings last quarter?

Biotricity Inc. (OTCMKTS:BTCY) released its quarterly earnings data on Thursday, August, 14th. The company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.06. The firm had revenue of $3.87 million for the quarter, compared to the consensus estimate of $3.80 million.
Read the conference call transcript.

When did Biotricity's stock split?

Biotricity shares reverse split on the morning of Monday, July 3rd 2023.The 1-6 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

How do I buy shares of Biotricity?

Shares of BTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biotricity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biotricity investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Broadcom (AVGO), Micron Technology (MU) and Bank of America (BAC).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/16/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:BTCY
• CIK: 1630113
• Web: www.biotricity.com
• Phone: (650) 832-1626
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.42 million
• Net Margins: -37.33%
• Pretax Margin: -37.32%
• Return on Equity: N/A
• Return on Assets: -94.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.24
• Quick Ratio: 0.15

Sales & Book Value

• Annual Sales: $12.06 million
• Price / Sales: 1.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.29) per share
• Price / Book: -0.53

Miscellaneous

• Outstanding Shares: 24,912,000
• Free Float: 22,396,000
• Market Cap: $16.97 million
• Optionable: Not Optionable
• Beta: 1.19